insider trade RSS

Regions

Current Selected: USA
Show All Countries ▾

Market Overview:

LifePoint Hospitals Inc (LPNT) Director KONDRACKE MARGUERITE's Insider Stock Buys and Sells

Also See:

To find out why GuruFocus thinks data on insider trade are interesting, read

Filter by:
Select to drill down:

Display Those with At Least Shares
Display Stocks That are within of

Recent Filings Activity

Symbol Company Insider Position Date Buy/Sell Shares Trade Price ($) Cost ($1000) Price Change
Since Trade (%)
Yield (%)P/EMarket Cap ($M)Details
LPNTLifePoint Hospi...KONDRACKE MARGUERITEDirector2014-03-12Sell2,000$51.4910345.27 0.0024.503376.600 Link
BFAMBright Horizons...KONDRACKE MARGUERITEDirector2013-01-30Buy10,000$2222084.86 0.0036.402685.100 Link

Add this list into my watchlist/portfolio:

1. Add or remove tickers (Comma separated)

2. Select destination portfolio


You need to log in to proceed

3. Click the button to finish



LPNT is Owned by These Gurus:
Guru Name Portfolio Date* Current Shares (?) % of Total Assets (?) Change from Last Holdings (?)
Larry Robbins 2014-06-301,468,4290.53%-65.7%
HOTCHKIS & WILEY 2014-06-301,758,5160.39%-6.09%
David Dreman 2014-06-3075,5330.35%-55.91%
Diamond Hill Capital 2014-06-30374,5080.18%+31.84%
Louis Moore Bacon 2014-06-3070,0000.1%New Buy
Paul Tudor Jones 2014-06-3015,6000.04%+13.87%
Jim Simons 2014-06-3066,3300.01%New Buy
Premium Most recent portfolio changes are included for Premium Members only!


Related News and Stories:

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as Conversion of derivative security or Exercise of Options are not included. Insiders are only limited to Officers and/or Directors of the company.

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK